pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
camizestrant · news · pharmadog
← back to camizestrant
News mentioning camizestrant
16
stories
26d
STAT+: Pharmalittle: We’re reading about another AstraZeneca trial failure, a Novo name change, and more
stat
29d
STAT+: Breast cancer pill from AstraZeneca misses mark in pivotal trial
stat
Sep 10, 26
In first interview as FDA oncology chief, Angelo de Claro vows to ‘continue the innovation’ behind OCE legacy
fiercebiotech
Sep 8, 26
AstraZeneca’s SERD pill overcomes adcomm defeat to win FDA nod in breast cancer
biospace
Sep 8, 26
FDA approves AstraZeneca’s Etcamah, opening ctDNA-guided treatment paradigm in breast cancer
fiercebiotech
Sep 7, 26
FDA approves AstraZeneca’s oral SERD for breast cancer despite negative adcomm vote
endpoints
Sep 7, 26
Guardant wins FDA nod for diagnostic guiding use of AstraZeneca’s Etcamah
fiercebiotech
Sep 4, 26
FDA Grants Accelerated Approval to a New Breast Cancer Treatment
fda press
Aug 3, 26
‘Unlikely’ AstraZeneca-BMS mega-merger would be largest pharma deal ever
biospace
Jul 24, 26
Novo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myeloma
biopharma dive
Jul 22, 26
Wainua flop narrows AstraZeneca’s path to $80B goal ahead of high-risk readouts
biospace
May 27, 26
AstraZeneca's breast cancer PDUFA delayed; Arrowhead aims at same obesity target as Wave
endpoints
May 8, 26
Poll Results Highlight Breast Cancer Abstracts of Interest at ASCO 2026
onclive
May 6, 26
ASCO 2026 HR+ and HER2+ Breast Cancer Preview: Read up on the Insights to Know Before You Go
onclive
May 1, 26
Summit’s ‘self-inflicted’ stumble; Esperion’s take-private deal
biopharma dive
Apr 30, 26
FDA's oncology advisors vote against 'new paradigm' in AstraZeneca trial
endpoints
